Article
Cardiac & Cardiovascular Systems
Zhenjie Liu, Jinyi Chen, Xin Xu, Fen Lan, Minzhi He, Changming Shao, Yongshan Xu, Pan Han, Yibing Chen, Yongbin Zhu, Man Huang
Summary: This study investigated the short-term outcomes of using VA-ECMO with or without PMT to treat acute life-threatening massive or submassive PE. The results showed that an ECMO-first strategy complemented with PMT can effectively stabilize hemodynamics and improve survival rates in these patients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Medicine, General & Internal
Ryan P. Barbaro, Graeme MacLaren, Philip S. Boonstra, Alain Combes, Cara Agerstrand, Gail Annich, Rodrigo Diaz, Eddy Fan, Katarzyna Hryniewicz, Roberto Lorusso, Matthew L. Paden, Christine M. Stead, Justyna Swol, Theodore J. Iwashyna, Arthur S. Slutsky, Daniel Brodie
Summary: The study examined the use of ECMO for COVID-19 patients during 2020 globally, showing lower in-hospital mortality rates in early-adopting ECMO centres and higher rates in late-adopting centres.
Article
Cardiac & Cardiovascular Systems
Ilhan Inci, Jonas Peter Ehrsam, Dirk Van Raemdonck, Laurens Joseph Ceulemans, Thorsten Krueger, Angela Koutsokera, Marco Schiavon, Eleonora Faccioli, Mario Nosotti, Lorenzo Rosso, Frank D'Ovidio, Miguel Leiva-Juarez, Clemens Aigner, Alexis Slama, Waleed Saleh, Khaled Manaa Alkattan, Pascal Alexandre Thomas, Geoffrey Brioude, Alberto Benazzo, Konrad Hoetzenecker
Summary: This study investigated the outcomes of recipients bridged to a first-time retransplantation (ReTx) by extracorporeal life support (ECLS). The results showed that the overall survival of the ECLS-ReTx group was significantly worse compared to the regular-ReTx and index-Tx groups. Risk factors such as recipient age, intertransplant interval, primary graft dysfunction as transplant indication, and type of ECLS were identified as significant factors affecting mortality in ECLS-ReTx recipients.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Review
Dermatology
Edward W. W. Cowen, Eric R. R. Tkaczyk, Scott A. A. Norton, Kieron S. S. Leslie
Summary: The 2022 mpox outbreak has become a global concern, coinciding with the ongoing COVID-19 pandemic. Unlike COVID-19, mpox primarily manifests as skin findings, which can be mistaken for other common skin diseases, especially sexually transmitted infections. This Special Communication provides a comprehensive overview of the evolution of mpox skin findings since its first observation in humans in 1970 until the current multinational outbreak.
Review
Medicine, General & Internal
Dubravka Sipus, Kristina Krzelj, Zeljko Duric, Hrvoje Gasparovic, Davor Milicic, Jadranka Separovic Hanzevacki, Daniel Lovric
Summary: Heart transplant remains the gold standard therapy for end-stage heart failure, but using ECMO as a bridge to transplant may be a solution for critically ill patients. However, further research is needed to determine the superiority of direct bridging compared to bridging to durable MCS.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Cell Biology
Ali Hassanzadeh, Amjad Hussein Altajer, Heshu Sulaiman Rahman, Marwan Mahmood Saleh, Dmitry O. Bokov, Walid Kamal Abdelbasset, Faroogh Marofi, Majid Zamani, Yoda Yaghoubi, Mahboubeh Yazdanifar, Yashwant Pathak, Max Stanley Chartrand, Mostafa Jarahian
Summary: MSC-based therapy in cancer treatment is attracting attention due to their tumor-targeting properties, although controversial, increasing evidence suggests their inhibitory effects on tumor cells. Research focuses on using MSCs as delivery vehicles for chemotherapeutic drugs, immune cell-activating cytokines, and exploring their potential in inducing tumor regression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Engineering, Biomedical
Vittorio Scaravilli, Jacopo Fumagalli, Lorenzo Rosso, Federico Polli, Mauro Panigada, Chiara Abbruzzese, Stefania Crotti, Alfredo Lissoni, Mario Nosotti, Antonio Pesenti, Alberto Zanella, Giacomo Grasselli
Summary: The use of a novel no-heparin management approach during ECMO bridging to lung transplantation (LuTX) can effectively reduce the risk of perioperative bleeding, even in high-risk patients. Prospective studies are needed to further validate the effectiveness of this strategy.
Editorial Material
Cardiac & Cardiovascular Systems
Yatrik Patel, John W. Stokes, Whitney D. Gannon, James T. Zorn, Jordan Hoffman, Ashish S. Shah, Matthew Bacchetta
Summary: This article presents a novel approach to provide optimal support for patients with concomitant cardiac and pulmonary failure, using a minimal access approach to successfully bridge the patient to heart-lung transplant.
ANNALS OF THORACIC SURGERY
(2022)
Article
Cardiac & Cardiovascular Systems
Ioannis Mastoris, Joseph E. Tonna, Jinxiang Hu, Andrew J. Sauer, Nicholas A. Haglund, Peter Rycus, Yu Wang, William J. Wallisch, Travis O. Abicht, Matthew R. Danter, Ryan J. Tedford, James C. Fang, Zubair Shah
Summary: The use of ECMO as a bridge to advanced therapies, such as OHT or LVAD, has been increasing over the past decade. This study found that there was no significant difference in in-hospital mortality between LVAD and OHT, but the length of stay was longer for OHT.
CIRCULATION-HEART FAILURE
(2022)
Article
Pediatrics
John S. Kim, Cindy S. Barrett, Robert W. Hyslop, Shannon M. Buckvold, Katja M. Gist
Summary: This study examines the demographics and in-hospital mortality of children with pulmonary embolism who received Extracorporeal Membrane Oxygenation (ECMO) from 2007 to 2018. Out of the 56 patients identified, 33 (61%) survived. No significant differences were found in the demographics or ECMO details between survivors and non-survivors. However, non-survivors had a higher incidence of pulmonary bleeding compared to survivors.
FRONTIERS IN PEDIATRICS
(2022)
Review
Pediatrics
Brandy Johnson, Shoshana Leftin Dobkin, Maureen Josephson
Summary: Neonates with progressive respiratory failure should be referred for subspecialty evaluation and lung transplantation consideration. ECMO may be considered for severe cardiopulmonary dysfunction with a high likelihood of death, either in reversible medical conditions or while awaiting lung transplantation. The risks and benefits of ECMO should be assessed individually. More research is needed to study the outcomes of bridging techniques in neonatal transplant recipients.
PAEDIATRIC RESPIRATORY REVIEWS
(2022)
Article
Cardiac & Cardiovascular Systems
Jawad Salman, Beeke-Alina Bernhard, Fabio Ius, Reza Poyanmehr, Wiebke Sommer, Khalil Aburahma, Hani Alhadidi, Thierry Siemeni, Christian Kuehn, Murat Avsar, Axel Haverich, Gregor Warnecke, Igor Tudorache
Summary: This study aimed to identify risk factors for the need of intra-operative ECMO use in lung transplant patients with pulmonary fibrosis. Factors such as preoperative proof of pulmonary hypertension, mean pulmonary arterial pressure, and pulmonary vascular resistance were identified as risk factors, while increased recipient body surface area and higher cardiac output were protective factors. The post-operative course was found to be more complicated in the ECMO+ group, although long-term survival did not differ significantly among groups.
ANNALS OF THORACIC SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Kristen T. Carter, Robert O'Brien, Sharon B. Larson, Lawrence L. Creswell, Matthew Kutcher, David A. Baran, Jack G. Copeland, Hannah Copeland
Summary: This retrospective study on heart transplant recipients found that patients bridged to heart transplant with venoarterial extracorporeal membrane oxygenation had lower survival rates. Recipients requiring different forms of mechanical support had relatively longer survival times, emphasizing the importance of careful monitoring for patients on extracorporeal membrane oxygenation.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2022)
Article
Critical Care Medicine
Matthieu Schmidt, Elise Langouet, David Hajage, Sarah Aissi James, Juliette Chommeloux, Nicolas Brechot, Petra Barhoum, Lucie Lefevre, Antoine Troger, Marc Pineton de Chambrun, Guillaume Hekimian, Charles-Edouard Luyt, Martin Dres, Jean-Michel Constantin, Muriel Fartoukh, Pascal Leprince, Guillaume Lebreton, Alain Combes
Summary: This study compared the characteristics and outcomes of patients receiving ECMO treatment for severe COVID-19 ARDS before and after July 1, 2020, finding a significant increase in 90-day mortality after July 1, 2020. This increase in mortality may be partly explained by increased lung damage and failure of non-invasive oxygenation strategies before intubation.
Article
Critical Care Medicine
Matteo Di Nardo, Danilo Alunni Fegatelli, Marco Marano, Jacob Danoff, Hong K. Kim
Summary: This study described the use of extracorporeal membrane oxygenation (ECMO) in the management of pediatric poisoning in the United States and identified predictors of mortality. It found that ECMO can improve the hemodynamic and metabolic status of poisoned pediatric patients. Persistent hypotension, acidemia/acidosis, and elevated Pao(2) after 24 hours of ECMO were associated with mortality.
CRITICAL CARE MEDICINE
(2022)